Login about (844) 217-0978

Alan Rigby

In the United States, there are 24 individuals named Alan Rigby spread across 15 states, with the largest populations residing in California, Idaho, Massachusetts. These Alan Rigby range in age from 45 to 79 years old. Some potential relatives include Amy Wolf, Alex Wolf, Shari Wolf. The associated phone number is 801-274-0554, along with 6 other potential numbers in the area codes corresponding to 617, 435, 865. For a comprehensive view, you can access contact details, phone numbers, addresses, emails, social media profiles, arrest records, photos, videos, public records, business records, resumes, CVs, work history, and related names to ensure you have all the information you need.

Public information about Alan Rigby

Resumes

Resumes

Passanger Service Agent

Alan Rigby Photo 1
Location:
Salt Lake City, UT
Industry:
Airlines/Aviation
Work:
Airserv Corp 2006 - 2011
Passanger Service Agent

Cnc Programmer And Machinist

Alan Rigby Photo 2
Location:
Knoxville, TN
Industry:
Machinery
Work:
Moldesign Injection Molds Sep 2010 - Oct 2013
Machinist and Moldmaker Navus Automation, Inc. Sep 2010 - Oct 2013
Cnc Programmer and Machinist Gc Services Jan 2009 - Mar 2009
Account Representative
Education:
University of Tennessee, Knoxville 1997 - 2005
Skills:
Continuous Improvement, Machining, Manufacturing Engineering, Manufacturing, Solidworks

Alan Rigby

Alan Rigby Photo 3
Location:
Greater New York City Area
Industry:
Biotechnology

Sales-Plant Wide Filtration At Air Power, Inc

Alan Rigby Photo 4
Location:
P/O Box 544, Mabelvale, AR
Industry:
Industrial Automation
Work:
Air Power, Inc.
Sales-Plant Wide Filtration at Air Power, Inc

Retired

Alan Rigby Photo 5
Location:
Findley Lake, NY
Industry:
Religious Institutions

Research Manager

Alan Rigby Photo 6
Location:
428 east 5Th Ave, Salt Lake City, UT 84103
Industry:
Research
Work:
University of Utah College of Mines and Earth Science
Research Manager University of Utah
Research Manager
Education:
University of Utah 1987 - 1995
Bachelors, Geology, Chemistry, Environmental Science, Geophysics Taylorsville High School
Skills:
Environmental Science, Field Work, Research, Arcgis, Geology, Microsoft Office, Science, Earth Science, Data Analysis, Gis, Project Management, Management, Financial Analysis
Languages:
English

Alan Rigby - Knoxville, TN

Alan Rigby Photo 7
Work:
Moldesign - Knoxville, TN Sep 2010 to Oct 2013
Machinist/Moldmaker Akard Commutator of Tennessee Mar 2009 to Sep 2010
V-ring Molder/Oven Operator Navus Automation - Knoxville, TN Mar 2008 to Jan 2009
CNC programmer and operator Cedar Bluff Cycles - Knoxville, TN Apr 2004 to Dec 2008
High end bicycle sales, assembly, and service Cedar Bluff Cycles - Knoxville, TN Dec 2005 to Apr 2006
CNC operator
Education:
Pellissippi State Technical Community College - Knoxville, TN
Associate of Applied Science in Mechanical University of Tennessee - Knoxville, TN
GD&T

Alan Rigby - Findley Lake, NY

Alan Rigby Photo 8
Work:
University of California at Los Angeles - Los Angeles, CA
Asst. Track & Field Coach
Education:
Slippery Rock University - Slippery Rock, PA
Bachelor of Science in Sport, Phys. Ed. & Health Science Stetson University - DeLand, FL
Masters Program in Counseling
Background search with BeenVerified
Data provided by Veripages

Publications

Us Patents

Inhibition Of Sgk1 In The Treatment Of Heart Conditions

US Patent:
2018024, Aug 30, 2018
Filed:
Feb 8, 2018
Appl. No.:
15/891626
Inventors:
- Boston MA, US
Saumya Das - Lexington MA, US
Alan C. Rigby - Newton MA, US
International Classification:
A61K 31/513
A61K 38/43
C07K 16/40
Abstract:
The present invention relates to the treatment of acquired and genetic heart conditions in a subject by the inhibition of SGK1, including Long QT syndrome and cardiovascular disease, including dilated cardiomyopathy. Cardiovascular diseases treatable by SGK1 inhibition include heart failure, arrhythmia, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure. The present invention also identifies selective inhibitors of SGK1. The method comprises administering to the subject a therapeutically effective amount of an inhibitor of SG.

Inhibition Of Sgk1 In The Treatment Of Heart Conditions

US Patent:
2020019, Jun 25, 2020
Filed:
Sep 17, 2019
Appl. No.:
16/573333
Inventors:
- Boston MA, US
Saumya Das - Lexington MA, US
Alan C. Rigby - Glen Ridge NJ, US
International Classification:
A61K 31/513
C07K 16/40
A61K 38/43
Abstract:
The present invention relates to the treatment of acquired and genetic heart conditions in a subject by the inhibition of SGK1, including Long QT syndrome and cardiovascular disease, including dilated cardiomyopathy. Cardiovascular diseases treatable by SGK1 inhibition include heart failure, arrhythmia, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure. The present invention also identifies selective inhibitors of SGK1. The method comprises administering to the subject a therapeutically effective amount of an inhibitor of SG.

Conopeptides

US Patent:
6307014, Oct 23, 2001
Filed:
Aug 19, 1998
Appl. No.:
9/136769
Inventors:
Bruce Furie - Wellesly MA
Barbara C. Furie - Wellesly MA
Johan Stenflo - S-21620 Malmo, SE
Alan C. Rigby - Boston MA
Peter Roepstorff - DK-7000 Fredericia, DK
International Classification:
C07K 1400
C07K 14435
US Classification:
530324
Abstract:
Substantially pure conopeptides containing. gamma. -carboxyglutamic acid are disclosed.

Identification And Use Of Small Molecules To Modulate Transcription Factor Function And To Treat Transcription Factor Associated Diseases

US Patent:
2011007, Mar 24, 2011
Filed:
Mar 19, 2010
Appl. No.:
12/727740
Inventors:
Peter Oettgen - Brookline MA, US
Alan C. Rigby - Newton MA, US
Towia Libermann - Newton MA, US
Assignee:
BETH ISRAEL DEACONESS MEDICAL CENTER - Boston MA
International Classification:
C40B 30/02
A61K 31/136
A61K 31/36
A61K 31/52
A61K 31/5415
A61K 31/167
A61K 31/17
A61K 31/428
A61K 31/225
A61K 31/37
A61K 31/443
C07D 317/58
C07D 473/38
C07D 279/16
C07C 233/29
C07C 275/40
C07C 321/26
C07D 317/68
C07D 417/12
C07C 233/33
C07C 271/28
C07D 407/06
C07D 405/12
C07D 317/66
C07C 275/38
A61P 1/00
A61P 29/00
A61P 17/06
A61P 27/02
A61P 35/00
US Classification:
5142242, 506 8, 514646, 514466, 51426337, 514621, 514597, 514367, 514629, 514533, 514457, 514338, 514594, 549440, 544276, 544 52, 564169, 564 49, 564440, 549436, 548159, 564223, 560 26, 549285, 5462837, 549439, 564 44
Abstract:
The present invention relates to methods of identifying small molecule candidate agents capable of modulating transcription factor function such that the function/expression of a target transcription factor and/or proteins downstream of this target protein comprises the screening of small molecule libraries using in silico high throughput docking for candidate small molecules/agents that are selectively identified for their ability to target and disrupt the transcription factor-DNA interface through unique transcription factor and/or DNA descriptors that are defined within a pharmacophore, and then testing/evaluating the candidate agents identified above through one or more in vitro assays for their ability to modulate transcription factor function including expression of this target protein and/or proteins that are downstream of the target transcription factor. The present invention also relates to various compounds described herein (e.g., a compound of Formula XI), their pharmaceutically acceptable salts and to methods of using said compounds as described herein.

Identification And Use Of Small Molecules To Modulate Transcription Factor Function And To Treat Transcription Factor Associated Diseases

US Patent:
2010012, May 13, 2010
Filed:
May 6, 2009
Appl. No.:
12/436685
Inventors:
Peter Oettgen - Brookline MA, US
Alan Rigby - Newton MA, US
Towia Libermann - Newton MA, US
International Classification:
A61K 31/54
C40B 30/02
A61K 31/36
A61K 31/522
A61K 31/17
A61K 31/13
C07D 279/06
C07D 473/00
C07D 317/44
C07C 273/00
C07C 211/00
US Classification:
5142242, 506 8, 514466, 51426337, 514597, 514645, 544 53, 544276, 549443, 564 49, 564428
Abstract:
The present invention relates to methods of identifying small molecule candidate agents capable of modulating transcription factor function such that the function/expression of a target transcription factor and/or proteins downstream of this target protein comprises the screening of small molecule libraries using in silico high throughput docking for candidate small molecules/agents that are selectively identified for their ability to target and disrupt the transcription factor-DNA interface through unique transcription factor and/or DNA descriptors that are defined within a pharmacophore, and then testing/evaluating the candidate agents identified above through one or more in vitro assays for their ability to modulate transcription factor function including expression of this target protein and/or proteins that are downstream of the target transcription factor.

Androgen Receptor Inhibitors And Methods Of Use Thereof

US Patent:
2014008, Mar 27, 2014
Filed:
Dec 14, 2011
Appl. No.:
13/994679
Inventors:
Alan C. Rigby - Glen Ridge NJ, US
Steven P. Balk - Needham MA, US
Kumaran Shanmugasundaram - North Plainfield NJ, US
Howard C. Shen - Pasadena CA, US
Assignee:
BETH ISRAEL DEACONESS MEDICAL CENTER - Boston MA
International Classification:
C07D 317/58
C12Q 1/66
US Classification:
514465, 549443, 435375, 435 8
Abstract:
The present invention relates to novel aryl sulfonamide compounds use of such compounds in the inhibition of androgen receptor and in the treatment of various diseases, disorders or conditions related to androgen receptor.

Vitamin D Receptor Agonists And Uses Thereof

US Patent:
2014037, Dec 25, 2014
Filed:
Jul 11, 2012
Appl. No.:
14/232196
Inventors:
Peter Kang - Lexington MA, US
Ananth Karumanchi - Chestnut Hill MA, US
Santosh Khedkar - Somerville MA, US
Alan Rigby - Newton MA, US
Ravi I. Thadhani - Boston MA, US
Assignee:
Beth Israel Deaconess Medical Center, In. - Boston MA
International Classification:
C07D 215/54
C07C 311/21
US Classification:
514311, 514603
Abstract:
This invention features vitamin D receptor agonists, and their use in treating bone disorders, cardiovascular disease, hyperparathyroidism, immune disorders, proliferative disease, renal disease, and thrombosis.

Compounds To Fibroblast Growth Factor Receptor-3 (Fgfr3) And Methods Of Treatment

US Patent:
2015016, Jun 18, 2015
Filed:
Dec 11, 2014
Appl. No.:
14/567063
Inventors:
- INDIANAPOLIS IN, US
- WALTHAM MA, US
Hans K. ERICKSON - Waltham MA, US
Dale L. LUDWIG - Denville NJ, US
Christopher M. MOXHAM - Princeton Junction NJ, US
Gregory D. PLOWMAN - New York NY, US
Alan C. RIGBY - Glen Ridge NJ, US
Assignee:
IMCLONE LLC - INDIANAPOLIS IN
IMMUNOGEN, INC. - WALTHAM MA
International Classification:
A61K 47/48
A61K 31/395
A61K 45/06
Abstract:
The invention provides conjugates that consist of a drug moiety agent and a cell binding agent that target human fibroblast growth factor receptor 3 (FGFR3). These conjugates have therapeutic use as they are designed and tailored to target a specific cell population and deliver a powerful cytotoxin inside the cell. The conjugate of the present invention has significant advantages over other conjugates known in the art by providing a targeted tumor therapy as well as bystander activity to neighboring cells in an important oncology receptor that is only moderately expressed.

FAQ: Learn more about Alan Rigby

How old is Alan Rigby?

Alan Rigby is 64 years old.

What is Alan Rigby date of birth?

Alan Rigby was born on 1960.

What is Alan Rigby's telephone number?

Alan Rigby's known telephone numbers are: 801-274-0554, 617-536-3746, 435-753-2823, 865-531-8451, 919-676-5993, 925-978-9257. However, these numbers are subject to change and privacy restrictions.

How is Alan Rigby also known?

Alan Rigby is also known as: Alan J Rigby, Julle Rigby, Alan Rilby, Julie A Rigby. These names can be aliases, nicknames, or other names they have used.

Who is Alan Rigby related to?

Known relatives of Alan Rigby are: Melissa Wells, James Wolf, Shari Wolf, Alex Wolf, Amy Wolf, Devin Rigby, Louise Rigby, Amy Rigby, Andrew Rigby, Clyde Rigby, Mary Barinaga, Rigby Clyde. This information is based on available public records.

What are Alan Rigby's alternative names?

Known alternative names for Alan Rigby are: Melissa Wells, James Wolf, Shari Wolf, Alex Wolf, Amy Wolf, Devin Rigby, Louise Rigby, Amy Rigby, Andrew Rigby, Clyde Rigby, Mary Barinaga, Rigby Clyde. These can be aliases, maiden names, or nicknames.

What is Alan Rigby's current residential address?

Alan Rigby's current known residential address is: 401 Ella, Sandpoint, ID 83864. Please note this is subject to privacy laws and may not be current.

What are the previous addresses of Alan Rigby?

Previous addresses associated with Alan Rigby include: 77 Highland Ave, Glen Ridge, NJ 07028; 1466 W 3500 S Apt 218, W Valley City, UT 84119; 123 1309, Logan, UT 84321; 194 W 3450 S, Logan, UT 84321; 250 500, Providence, UT 84332. Remember that this information might not be complete or up-to-date.

Where does Alan Rigby live?

Sandpoint, ID is the place where Alan Rigby currently lives.

How old is Alan Rigby?

Alan Rigby is 64 years old.

People Directory:

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z